Medicines Update.

Chris Capstick

The Pharmaceutical Benefits Scheme (PBS), delivered welcomed news for Australians living with biliary cancer this week with IMFINZI® (durvalumab) being made available for patients diagnosed with

PBAC recommends subsidised therapies for biliary and oesophageal cancers

Nikki Rynia

The Pharmaceutical Benefits Advisory Committee (PBAC) last week announced two positive recommendations for therapies that will benefit biliary and oesophageal cancer patients. The therapies brought

Cancer and Religious Fasting

Samantha Spokes

We spoke to Senior Oncology Dietitian, Lauren Atkins, and pancreatic cancer patient, Aida, for their thoughts on how to navigate religious fasting periods if you or a loved one is impacted by